molecules of the month


oral A2A receptor antagonist/inverse agonist

Ph. II for Parkinson’s Disease

2nd gen. A2A receptor antagonist

ASPET, March 9, 2023

Kyowa Kirin Co., Ltd., Shizuoka, JP

KW-6356, oral A2A receptor antagonist/inverse agonist, Ph. II for Parkinson’s Disease, 2nd gen. A2A receptor antagonist, ASPET, March 9, 2023, KYOWA KIRIN CO., LTD., SHIZUOKA, JP
8 mins read

A furan-containing insurmountable antagonist and inverse agonist of the adenosine A2A receptor for Parkinson’s disease. Kyowa Kirin’s KW-6356, or sipagladenant, is a non-xanthine A2A receptor intended to treat Parkinson’s disease. Unlike Kyowa Kirin’s recently US-approved neutral antagonist, istradefylline, the molecule is an insurmountable antagonist and inverse agonist, both of which may contribute to better efficacy. Unfortunately, despite positive clinical results, the molecule was discontinued for commercial reasons. The molecule is scientifically notable for the GPCR co-crystal structures which provide insight into GPCR insurmountable antagonism and inverse agonism. Antagonism of the A2A receptor is a clinically validated, non-dopaminergic approach to Parkinson’s motor symptom relief. In PD patients, decreased dopamine signaling due to loss of dopaminergic neurons leads to an increase in…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: